Based on the high-dose data, AC Immune intends to advance to later-stage development of ACI-35.030, which according to the company is the first AD vaccine candidate designed to generate antibodies targeting pathological pTau in the brain. The company also plans to launch clinical studies of the optimized ACI-24 during the first half of this year . . .
Home Neurological Disorders Alzheimers Jabbing at Alzheimer’s: AC Immune Takes Precision Approach to Vaccines

- Neurological Disorders
- Alzheimers
- Drug Discovery
- Eli Lilly
- GEN Edge
- Genentech
- Janssen Biotech
- Parkinsons
- Therapeutics
- Vaccine Development
- Vaccines
Jabbing at Alzheimer’s: AC Immune Takes Precision Approach to Vaccines
The Swiss biopharma shows early clinical data for Janssen-partnered pTau shot and preclinical success for the wholly-owned prospect targeting Aβ amyloid.
[Source: AC Immune]